Actualités Acceleron Pharma Inc - XLRN | Actions NASDAQ

Votre Hub pour des idées et discussions en direct en temps réel

Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer

Believes Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process Remains Confident in Company’s Standalone...

Amended Tender Offer Statement by Third Party (sc To-t/a)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE...

Amended Statement of Ownership: Solicitation (sc 14d9/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Amended Statement of Ownership: Solicitation (sc 14d9/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Amended Statement of Ownership: Solicitation (sc 14d9/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No...

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer

Believes Now Is the Wrong Time to Cash out of Acceleron, Given Company’s Strong Momentum and Near-Term Inflection Point Coming from Phase 3...

Amended Tender Offer Statement by Third Party (sc To-t/a)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE...

Amended Statement of Ownership: Solicitation (sc 14d9/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Quarterly Report (10-q)

0001280600false2021Q3--12-3100012806002021-01-012021-09-30xbrli:shares00012806002021-11-01iso4217:USD00012806002021-09-3000012806002020-12-31is...

Current Report Filing (8-k)

0001280600false00012806002021-11-042021-11-04...

Acceleron Reports Third Quarter 2021 Financial Results

- Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL®...

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

Remains Opposed to Sale of Acceleron to Merck at Current Price and Plans Not to Tender Its Shares Believes Company Has Strong Momentum and...

Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales

- Acceleron expects to report approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of...

Statement of Ownership: Solicitation (sc 14d9)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLI...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Acceleron Pharma Inc (XLRN)

Votre Hub pour des idées et discussions en direct en temps réel

XLRN Actualités

Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer

Amended Tender Offer Statement by Third Party (sc To-t/a)

Amended Statement of Ownership: Solicitation (sc 14d9/a)

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Ownership: Solicitation (sc 14d9/a)

Amended Statement of Ownership: Solicitation (sc 14d9/a)

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer

Amended Tender Offer Statement by Third Party (sc To-t/a)

Amended Statement of Ownership: Solicitation (sc 14d9/a)

Quarterly Report (10-q)

Current Report Filing (8-k)

Acceleron Reports Third Quarter 2021 Financial Results

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales

Statement of Ownership: Solicitation (sc 14d9)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Acceleron Pharma Inc (XLRN) Actualités

Acceleron Pharma Inc (XLRN)

Votre Hub pour des idées et discussions en direct en temps réel

XLRN Actualités

Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer

Amended Tender Offer Statement by Third Party (sc To-t/a)

Amended Statement of Ownership: Solicitation (sc 14d9/a)

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Ownership: Solicitation (sc 14d9/a)

Amended Statement of Ownership: Solicitation (sc 14d9/a)

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer

Amended Tender Offer Statement by Third Party (sc To-t/a)

Amended Statement of Ownership: Solicitation (sc 14d9/a)

Quarterly Report (10-q)

Current Report Filing (8-k)

Acceleron Reports Third Quarter 2021 Financial Results

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales

Statement of Ownership: Solicitation (sc 14d9)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres